Eli Lilly remains a Buy despite a recent 12% price decline, supported by strategic developments and valuation upside, even as it faces challenges. LLY faces near-term headwinds from Zepbound price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results